6533b831fe1ef96bd1298672
RESEARCH PRODUCT
Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.
Petra StaubachAndrea SchützAdriane Peveling-oberhagNicole SchoepkeMartin MetzKarsten WellerMarcus MaurerThilo JakobSabine Müllersubject
AdultMalemedicine.medical_specialtyUrticariaImmunologyTreatment outcomePlacebo-controlled studyMEDLINEDrug ResistanceHistamine AntagonistsOmalizumabOmalizumablaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawInternal medicineAnti-Allergic AgentsImmunology and AllergyMedicineHumansbusiness.industryMiddle AgedSymptomatic dermographismTreatment Outcome030228 respiratory systemMulticenter studyFemalebusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2016-08-03 | The Journal of allergy and clinical immunology |